Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment (No. 1) Determination 2024

I, Mary Warner, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 14 May 2024

Mary Warner

Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medicare Benefits and Digital Health Division

Health Resourcing Group

Department of Health and Aged Care

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 1

1  Name

  This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment (No. 1) Determination 2024.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments to co-dependant pathology services

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1  Schedule 1 (cell at item 73295, column 2)

Repeal the cell, substitute:

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS), in a patient with:

(a)    advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or

(b)    triple negative early breast cancer; or

(c)    hormone receptor positive, HER2-negative, early breast cancer with one or more high-risk characteristics.

Applicable once per lifetime.